Oropharyngeal candidiasis treatment

Oropharyngeal candidiasis treatment PO 10 mg 5 times/day for 14 days. Oropharyngeal candidiasis prophylaxis PO 10 mg 3 times/day Dermatophytosis, cutaneous candidiasis Topical 2 times/day. Therapeutic effect may take up to 8 wk. 

Inhaled steroids (commonly used are beclomethasone, budesonide, triamcinolone, fluticasone, flunisolide) appear to attenuate the inflammatory response, to reduce bronchial hyperreactivity, to decrease exacerbations and to improve health status they may also reduce the risk of myocar dial infar ction, but they do not modify the longterm decline in lung function. Whether- steroids affect mortality remains unclear. Many patients appear to be resistant to steroids and large, long-term trials have shown only limited effectiveness of inhaled corticosteroid ther apy. Certainly, the benefit from steroids is smaller in COPD than in asthma. Topical side-effects of inhaled steroids are oropharyngeal candidiasis and hoarse voice. At the normal doses systemic side-effects of inhaled steroids have not been firmly established. The current recommendation is that the addition of inhaled gluco-coiticosteroids to bronchodilator treatment is appropriate for patients with severe to veiy sever e COPD. 

Recognize when topical versus oral treatment is indicated for a patient with oropharyngeal candidiasis, esophageal candidiasis, and fungal skin infections. 

Oropharyngeal candidiasis is often a presumptive diagnosis based on signs and symptoms, along with the resolution of them after treatment with antifungal agents. 

Oropharyngeal candidiasis 200 mg on the first day, followed by 100 mg once daily. Continue treatment for at least 2 weeks to decrease the likelihood of relapse. 

Oropharyngeal candidiasis - 200 mg/day for 1 to 2 weeks. Vigorously swish the solution in the mouth (10 ml at a time) for several seconds and swallow. For patients with oropharyngeal candidiasis unresponsive/refractory to treatment with fluconazole tablets, the recommended dose of itraconazole is 100 mg twice daily. Expect clinical response in 2 to 4 weeks. Patients may be expected to relapse shortly after discontinuing therapy. Limited data on the safety of long-term use (more than 6 months) of the oral solution are available at this time. 

Grim SA, Smith KM, RomaneUi F, Ofotoknn 1. Treatment of azole-resistant oropharyngeal candidiasis with topical amphotericin. Ann Pharmacother 2002 36(9) 1383-6. 

Unlabeled Uses Prophylaxis and treatment of oropharyngeal candidiasis, tinea barbae, tinea capitis... 

A special problem caused by inhaled corticosteroids is the occurrence of oropharyngeal candidiasis. The risk of this complication can be reduced by having patients gargle water and spit after each inhaled treatment. Hoarseness can also result from a direct local effect of inhaled corticosteroids on the vocal cords. These agents are remarkably free of other short-term complications in adults but may increase the risks of osteoporosis and cataracts over the long term. In children, inhaled corticosteroid therapy has been shown to slow the rate of growth, but this effect appears to be transient Asthma itself delays puberty, and there is no evidence that inhaled corticosteroid therapy in childhood influences adult height. 

Phillips P, De Beule K, Frechette G, Tchamouroff S, Vandercam B, Weitner L, Hoepelman A, Stingl G, Clotet B. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Chn Infect Dis 1998 26(6) 1368-73. 

Local adverse effects from ICSs include oropharyngeal candidiasis and dysphonia that are dose-dependent. The dysphonia appears to be due to a local corticosteroid-induced myopathy of the vocal cords. The use of a spacer device can decrease oropharyngeal deposition and thus decrease the incidence and severity of local side effects. In infants who require delivery through a facemask, the parent should clean the nasal-perioral area with a damp cloth following each treatment to prevent topical candidal infections. 

Patton LL, Bonito AJ, Shugars DA. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001 92 170-179. 

Oral use (troche) Treatment of oropharyngeal candidiasis prophylaxis of oropharyngeal candidiasis in specific groups of inununocompromised patients... 

Fluconazole-refractory oropharyngeal candidiasis is a common condition in human immunode-ciency virus (HIV) -positive patients. Twelve such patients were treated with 15 mL of a M. alterni-folia oral solution (Breath-Away) four times daily for 2 weeks, in a single center, open-label clinical trial. The solution was swished in the mouth for 30-60 s and then expelled, with no rinsing for at least 30 min. Clinical assessment was carried out on days 7 and 14, and also on days 28 and 42 of the follow-up. Two patients were clinically cured and six were improved after the therapy however, four remained unchanged and one deteriorated. The overall clinical response rate was thus 67% and was considered as a possible alternative antifungal treatment in such cases (Jandourek et al., 1998). 

ATC J02AC01 J02AX Use antifungal (treatment of vaginal, oropharyngeal and atrophic oral candidiasis)... 

If the patient has had oropharyngeal or esophageal candidiasis previously, determine what treatments were helpful to the patient in the past. 

Onychomycosis (capsules only) Treatment of onychomycosis of the toenail with or without fingernail involvement and onychomycosis of the fingernail because of dermatophytes Tinea unguium) in nonimmunocompromised patients. Oropharyngeal/esophageal candidiasis (oral solution only) Treatment of oropharyngeal or esophageal candidiasis. 

Severely neutropenic patients Itraconazole oral solution as treatment for oropharyngeal and/or esophageal candidiasis was not investigated in severely neutropenic patients. Because of its pharmacokinetic properties, itraconazole oral solution is not recommended for initiation of treatment in patients at immediate risk of systemic candidiasis. 

---